Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Clicks: 272
ID: 266439
2020
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
6.3
/100
21 views
21 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (9 words).
Try re-searching for a better abstract.
| Reference Key |
p2020lancetbaricitinib
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Richardson P;Griffin I;Tucker C;Smith D;Oechsle O;Phelan A;Rawling M;Savory E;Stebbing J;; |
| Journal | Lancet (London, England) |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
covid-19
sars-cov-2
humans
pubmed abstract
nih
national institutes of health
national library of medicine
pandemics
pneumonia
letter
viral / drug therapy*
pmid:32032529
pmc7137985
doi:10.1016/s0140-6736(20)30304-4
peter richardson
ivan griffin
justin stebbing
azetidines / therapeutic use*
betacoronavirus / drug effects*
coronavirus infections / drug therapy*
sulfonamides / therapeutic use*
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.